Source: Annual Congress 2009 - Epidemiology and management of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
H. Nitanai, M. Ogasawara, K. Yamauchi, N. Sasaki, Y. Utsumi, N. Suzuki, S. Akiyama, H. Nagashima, Y. Nakamura, H. Kobayashi, H. Inoue (Morioka, Toon, Japan). Biological analysis of the single codon deletion in Exon 19 of EGF receptor in non-small cell lung cancer responsive to gefitinib. Eur Respir J 2009; 34: Suppl. 53, 4692

Member's Comments

No comment yet.

Related content which might interest you: Frequency of T790M substitution in exon 20 of EGFR gene in brain metastases in chemotherapy-naive non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer Source: Eur Respir J 2011; 38: 903-910 Year: 2011 Polymorphisms in the interleukin-10 gene promoter are associated with susceptibility to non-small cell lung cancer (NSCLC) Source: Eur Respir J 2005; 26: Suppl. 49, 458s Year: 2005 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC). Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 Epithelial growth factor receptor (EGFR) mutation status and the treatment of non-small cell lung cancer (NSCLC): A population based quality assurance analysis Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer Source: Eur Respir Rev 2010 19: 186-196 Year: 2010 Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients Source: Eur Respir Rev 2014; 23: 390-392 Year: 2014 Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001 Targeting gene of insulin-like growth factor type I (IGF-I) on in vitro model of A549 cell line with triple-helix approach. Perspectives of gene therapy in non-small cell lung (NSCLC) cancer Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006 Toll-like receptor 3 is up-regulated and enhances anti-proliferative function in human non-small cell lung cancer Source: Annual Congress 2008 - Lung cancer and other malignant diseases involving the lungs Year: 2008 A blood-based test for epidermal growth factor receptor mutations in patients with non-small cell lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer. Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020